Beijing-based China Medical Technologies said this week that China's State Food and Drug Administration has approved its real-time PCR-based KRAS assay as a companion diagnostic test for the use of a targeted colorectal cancer drug.

KRAS mutations occur in 30 percent to 60 percent of colorectal cancers and are associated with poor response to EGFR inhibitors such as Amgen's Vectibix and Merck's Erbitux.

China Medical did not disclose the name of the drug for which its assay was approved as a companion diagnostic.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.